ClinicalTrials.gg
Not yet recruitingNCT06649747Updated Jun 26, 2025

Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain

A Phase 2 interventional study of AFA-281 in Lumbosacral Radiculopathy, sponsored by Afasci Inc. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Afasci Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate if the drug candidate AFA-281 works to treat chronic low back and leg pain caused by painful lumbosacral radiculopathy (PLSR) in adults. This trial will also evaluate the safety of AFA-281. The main questions it aims to answer are:

  • Does AFA-281 mitigate pain?
  • What are the side effects (if any)? Researchers will compare AFA-281 to a placebo (a look-alike substance that contains no drug) to see if AFA-281 works to treat chronic low back and leg pain.

Participants will:

  • Take drug AFA-281 or a placebo three times every day for 4 weeks
  • Visit the clinic once every 2 weeks for checkups and tests
  • Keep a diary of their pain scores and about mood and sleep questionnaires, and the number of times they use a rescue pain medicines.
Read the detailed description

This is a randomized, double-blind, placebo-controlled, multicenter Phase II study of the efficacy, safety, tolerability, and PK of oral AFA-281 in 300 patients with painful lumbosacral radiculopathy (PLSR). Patients will be randomized in to the placebo group or doses of AFA-281, titrated over 2 weeks to reach planned daily doses for Weeks 3 and 4. Trials will be conducted simultaneously at 3 sites to meet enrollment targets. The primary efficacy endpoint is 24-hour average pain score based on the 0-10-point Numeric Pain Rating Scale (NPRS) and key secondary endpoint is Oswestry Disability Index (ODI), rates of adverse events, and PK, among others.

02

Conditions studied

  • Lumbosacral Radiculopathy

Keywords

  • Analgesics
  • Inflammatory pain
  • Neurologic Diseases
  • Neuromuscular Diseases
  • Neuropathic pain,
  • Peripheral Nervous System Diseases
03

In context

Nervous System Diseases

758 studies on the registry are indexed under Nervous System Diseases; 217 are open to participants now.

This study's planned enrollment of 408 is above the median of 55 across 496 interventional studies indexed under Nervous System Diseases.

Browse Nervous System Diseases studies →

Lead sponsor

Afasci Inc is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form (ICF) indicating that the subject has been informed of the procedures to be followed, the experimental nature of the therapy, potential benefits, side effects, risks, and discomforts
  2. Men or nonpregnant, non-breastfeeding women 18 to 65 years of age who can read and understand written and spoken local language
  3. Clinical diagnosis of CLBP due to LSR in a dermatomal pattern (L4, L5, or S1) that has been present for at least 3 months at the time of screening.
  4. MRI imaging is done within 12 months before screening that does not provide evidence of exclusionary pathology (see exclusion criteria). CT is acceptable for subjects with for MRI.
  5. Willing to discontinue current pain medications from 2 weeks before randomization until the end of the clinical study (treatment).
  6. Numeric rating scale (NRS) ≥4 and ≤9 at screening based on the Patient's Global Impression of Severity (PGI-S)

Exclusion criteria

Exclusion Criteria:

  1. Neuropathic pain due to other causes rather than LSR (e.g. painful diabetic neuropathy, other neuropathy, spinal abscess, infection, hematoma or ; phantom limb pain)
  2. Has a history of peripheral neuropathy (e.g., due to diabetes, alcohol consumption, other causes, or idiopathic) or evidence of peripheral neuropathy upon neurological examination
  3. History of surgical intervention for LSR at the radicular level of the current pain episode.
  4. Current indication for neurosurgery (e.g. progressive motor loss due to compression) or planned surgical intervention for LSR within the duration of the study
  5. Has planned surgical intervention for PLSR within the duration of the study. (Subjects with persistent radicular pain after prior surgery are eligible.)
  6. Spinal stenosis with neurogenic claudication (pain present during walking and signs of significant lumbar stenosis on existing MRI or CT scan)
  7. Presence of spinal cord stimulator.
  8. /allergic reaction to other T-type calcium agents, such as (but not limited to) ethosuximide, zonisamide, and the mixed sodium and T-type calcium channel blocker lamotrigine and .
  9. Patients who failed a relatively adequate treatment with a tricyclic antidepressants (TAC), selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs)
  10. Concurrent illnesses that would be a to trial participation, including, but not limited to:

    1. Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than 6 months before screening
    2. (NYHA) Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled hypertension
    3. electrocardiographic () abnormality per the investigator assessment
    4. Has a history or risk of seizures or a history of epilepsy, clinically significant head injury, or related neurological disorders
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
408 participants (estimated)

Study arms

  • Active comparator
    Low dose

    Name: AFA-281; Dosage Form: 5 and 20mg; Dosage: 60mg daily three times a day (TID) for 28 consecutive days

    Drug: AFA-281

  • Active comparator
    Mid Dose

    Name: AFA-281; Dosage Form: 5 and 20mg; Dosage: 120 mg daily three times a day for 28 consecutive days

    Drug: AFA-281

  • Active comparator
    High Dose

    Name: AFA-281; Dosage Form: 5 and 20mg; Dosage: 240 mg daily three times a day for 28 consecutive days

    Drug: AFA-281

  • Placebo comparator
    Placebo

    Name: Placebo Dosage form: matching study drug Dosage: 0 mg daily three times a day for 28 consecutive days

    Drug: AFA-281

Interventions

  • A small molecule, orally available

06

What researchers measure

Primary outcomes

  1. Numeric Pain Rating Scale

    On a scale of 0 to 10, with 0 being no pain at all and 10 being the worst pain imaginable

    Time frame: 2 weeks baseline and 4 weeks of treatment, and 2 weeks after the end of treatment

  2. Safety- Number of Participants with Treatment-Related Adverse Events (AEs)

    AEs will be assessed by CTCAE v5.0.

    Time frame: Baseline (2 weeks) and 4 weeks of the treatment, and 4 weeks of followup

Secondary outcomes

  1. Tmax

    Blood samples collected and analyzed for Tmax

    Time frame: Predose and Day 28

  2. Cmax

    Blood samples collected and analyzed for Cmax

    Time frame: Predose and Day 28

  3. Half life

    Blood samples collected and analyzed for half life

    Time frame: Predose and Day 28

  4. AUC

    Blood samples collected and analyzed for AUC

    Time frame: Predose and Day 28

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Mar 2032, 59 months later.

Of 49 phase 2 interventional studies under Nervous System Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 59 months is above that.

Nervous System Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2024
First posted
Oct 21, 2024
StartEst.
Apr 1, 2027
Primary completionEst.
Mar 31, 2032
CompletionEst.
Mar 31, 2032
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06649747
Lead sponsor
Afasci Inc
Responsible party
Sponsor
First posted
Oct 21, 2024
Start date
Apr 1, 2027 (estimated)
Primary completion
Mar 31, 2032 (estimated)
Completion
Mar 31, 2032 (estimated)
Last update
Jun 26, 2025

Study contacts

Dennis Gilman, PhD
Contact
dpgilman@clindm-llc.com
7752250561
Xinmin Xie, MD, PhD
study director · Afasci Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AFA-281

Start the discussion